Valuation: LivaNova PLC

Market Cap 4.46B 22.45B 3.98B 3.68B 3.33B 6.23B 423B 6.34B 44.25B 17.52B 222B 16.73B 16.37B 699B P/E 2026 *
20.2x
P/E 2027 * 24.4x
Enterprise Value 4.53B 22.83B 4.05B 3.74B 3.39B 6.34B 430B 6.44B 44.99B 17.81B 225B 17.01B 16.65B 711B EV / Sales 2026 *
2.98x
EV / Sales 2027 * 2.68x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.64%
3 months+3.87%
6 months+30.88%
Current year+24.71%
Current year 41.64
Extreme 41.64
54.5
1 year 41.64
Extreme 41.64
54.5
3 years 29.88
Extreme 29.88
54.5
5 years 29.88
Extreme 29.88
54.5
10 years 29.88
Extreme 29.88
54.5
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 69 2015-10-18
Chairman 74 2021-06-08
Director/Board Member 62 2019-06-17
Change 5-day change 1-year change 3-year change Capi.($)
+2.64%-.--% - - 4.46B
+1.16%-1.13%-17.92%+8.27% 179B
+0.02%+4.24%-19.82%+16.53% 118B
-1.22%+0.70%+1.27%+31.80% 117B
+2.29%+17.36%-41.94%+9.49% 93.26B
-2.21%-2.91%+0.74%+75.30% 63.16B
-1.06%+1.75%+13.50%+80.00% 55.68B
-0.75%+3.73%+6.64%-22.28% 54.18B
-1.13%+0.00%-12.25%+31.02% 44.15B
+0.17%+5.85%-4.92%-10.64% 33.95B
Average -0.01%+3.60%-8.30%+24.39% 84.27B
Weighted average by Cap. +0.01%+3.09%-11.69%+22.47%

Financials

2026 *2027 *
Net sales 1.52B 7.67B 1.36B 1.26B 1.14B 2.13B 144B 2.16B 15.11B 5.98B 75.7B 5.71B 5.59B 239B 1.63B 8.21B 1.46B 1.34B 1.22B 2.28B 155B 2.32B 16.18B 6.41B 81.08B 6.12B 5.99B 256B
Net income 226M 1.14B 202M 187M 169M 316M 21.48B 322M 2.25B 889M 11.25B 849M 831M 35.48B 187M 942M 167M 154M 140M 261M 17.74B 266M 1.86B 735M 9.3B 701M 687M 29.31B
Net Debt 75M 378M 66.97M 61.87M 56.07M 105M 7.12B 107M 745M 295M 3.73B 281M 275M 11.76B -85M -428M -75.9M -70.12M -63.55M -119M -8.07B -121M -844M -334M -4.23B -319M -312M -13.33B
Projected Income Statement - Annual - LivaNova PLC
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
3,300
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - LivaNova PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
80.90USD
Average target price
90.55USD
Spread / Average Target
+11.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - LivaNova PLC